Professional Media briefs

Share this article:
Catherine DeAngelis will step down from her post as JAMA editor-in-chief next June, the journal said, and return to Johns Hopkins. During her 10-year career at the AMA-published medical publication, DeAngelis toughened conflict-of-interest guidelines, worked to require registration of clinical trials as a condition of publication and established the JAMA requirement that industry-sponsored clinical trials must have an independent academic statistician to review all data before a manuscript can be accepted and published. She was also criticized for letting some author conflicts go undisclosed.

A Columbia University study found that in 2007, 25 out of 32 consultants to medical device firms drawing $1 million-plus compensation failed to reveal those conflicts of interest in journal articles published the following year. The authors called for tougher disclosure policies at medical journals.

The FDA's Division of Drug Marketing, Advertising and Communication hit Baxter with a warning letter for a physician brochure for Aralast NP, expressing concern over “your continued violative promotion of your products” and citing two previous letters.
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Antidote: On Cystic Fibrosis treatments

Antidote: On Cystic Fibrosis treatments

Recent treatments in CF, including the inhaled antibiotic Tobramycin, have increased lifespan well into adulthood.

The $3 generic and the $1,000 pill: pharma outsiders just don't get it

The $3 generic and the $1,000 pill: pharma ...

What do you call the people who treat medical breakthroughs as if they were bank heists? Malicious? Uninformed? Not with it?

Leadership Exchange Uncut : The Agency-Client Relationship

Leadership Exchange Uncut : The Agency-Client Relationship

Click the above link to access MM&M's first Leadership Exchange Uncut e-book, "The Agency-Client Relationship"